scholarly journals Effectiveness of lidocaine patches in the treatment of post-herpetic neuralgia on the face: a systematic review and meta-analysis

2021 ◽  
Vol 10 (13) ◽  
pp. e482101321513
Author(s):  
Ricardo Grillo ◽  
Marília Coelho Oliveira Dutra Leal ◽  
Antônio Augusto Campanha ◽  
Claudio Roberto Pacheco Jodas ◽  
Rubens Gonçalves Teixeira
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Treatment Options ◽  
Cost Benefit ◽  
Post Herpetic Neuralgia ◽  
First Line ◽  
First Line Therapy ◽  
Cost Benefit Ratio ◽  
The Face ◽  
Morbid Conditions

The post-herpetic neuralgia (PHN) is one of the most chalenging neuropathies to resolve. There are many treatment options with varying degrees of effectiveness. This paper conducts a systematic review of the literature on lidocaine patches in the treatment of these neuralgia.  A systematic review according to the PRISMA guidelines on lidocaine patches in the treatment of postherpetic neuralgia. The PROPERO registration has been carried out. A meta-analysis was performed with RevMan 5.3. Nine articles were included according to criteria. A table of excluded articles and their reason was carried out. Lidocaine patches are effective in treating post-herpetic neuralgia and are safer than other treatments, making them available for elderly patients with co-morbid conditions when other treatments cannot be used due to side effects. Lidocaine patches should be considered the first line therapy in the treatment of post-herpetic neuralgia of the face because of their safety and cost-benefit ratio.

How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis

2006 ◽  
Vol 24 (11) ◽  
pp. 2131-2141 ◽  
Author(s):  
Hazel A Bradley ◽  
Charles Shey Wiysonge ◽  
Jimmy A Volmink ◽  
Bongani M Mayosi ◽  
Lionel H Opie
Keyword(s):  
Systematic Review ◽  
Beta Blockers ◽  
Meta Analysis ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

Outcomes of North American, Japanese, and European extensive-disease small cell lung cancer (ED-SCLC) patients under irinotecan-platinum or etoposide-platinum therapy: Systematic review and meta-analysis.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e18534-e18534
Author(s):  
Joao Paulo Da S.N. Lima ◽  
Andre Deeke Sasse ◽  
Emma C. Sasse ◽  
Lucas Vieira dos Santos
Keyword(s):  
Systematic Review ◽  
North American ◽  
Meta Analysis ◽  
Geographic Origin ◽  
First Line ◽  
First Line Therapy ◽  
Geographic Origins ◽  
One Year ◽  
Meta Analyses ◽  
The Impact

e18534 Background: Superiority of irinotecan-platinum (IP) regimens over etoposide-platinum (EP) in ED-SCLC has been extensively debated, with ethnic and pharmacogenomics issues hypothesized as causes of the divergent findings. We undertook a systematic review to scrutinize the data according to geographic origin. Methods: Randomized controlled trials comparing first-line EP doublets versus IP in ED-SCLC patients were searched in major meeting proceedings and databases. The outcomes were overall survival (OS), one-year survival, two-year survival, and safety. Meta-analyses were performed using random-effects model. Subgroup analyses and meta-regression were undertaken to compare and measure the impact of geographical origin of study over the estimated effect size. Results: Seven studies (2,029 patients) were included. IP improved OS worldwide (HR = 0.83; 95% CI 0.76-0.92; P>0.001; I²=0%). However, the impact of IP on OS was different according to geographic origin, with relevant benefit for Japanese, little benefit for North American/Australian and intermediate for European patients (P for interaction = 0.029, table 1). One year survival was homogenously improved from 34% with EP to 40% with IP (P=0.006). IP improved two year survival just for Japanese and European patients but not to North American ones (Table). Toxicity was not impacted by trial origin. Conclusions: IP improved survival for both Western and Eastern patients, but seems to exist a gradient of benefit according to geographic origins, with maximal benefit for Japanese, some relevant for European ones and little, if any, for North American/Australian patients. These findings should be taken in account when considering IP or EP as first-line therapy for ED-SCLC patients worldwide. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document